Umoja Biopharma to Present at the 7th Annual Evercore ISI HealthCONx Conference
26. November 2024 09:05 ET
|
Umoja Biopharma, Inc.
SEATTLE, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc. (Umoja), the clinical-stage leader of in vivo and off-the-shelf cell therapies that aim to realize the full reach and promise of...
Umoja Biopharma Appoints Scott Myers as Chairman of its Board of Directors
21. November 2024 08:05 ET
|
Umoja Biopharma, Inc.
SEATTLE, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc. (Umoja), the clinical-stage leader of in vivo and off-the-shelf therapies that aim to realize the full reach and promise of CAR...
Umoja Biopharma Announces Oral and Poster Presentations at the 66th American Society of Hematology Annual Meeting
05. November 2024 09:05 ET
|
Umoja Biopharma, Inc.
SEATTLE, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc. (Umoja), a transformative immunotherapy company creating off-the-shelf treatments that aim to extend the reach and effectiveness of...
Umoja Biopharma Announces Poster Presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer
04. Oktober 2024 09:05 ET
|
Umoja Biopharma, Inc.
SEATTLE, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc. (Umoja), a transformative immunotherapy company creating off-the-shelf treatments that aim to extend the reach and effectiveness of...
Umoja Biopharma Announces Oral Presentation at the American College of Rheumatology Convergence 2024
30. September 2024 16:30 ET
|
Umoja Biopharma, Inc.
SEATTLE, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc. (Umoja), a transformative immunotherapy company creating off-the-shelf treatments that aim to extend the reach and effectiveness of...
Umoja Biopharma to Present at the 9th Annual CAR-TCR Summit
11. September 2024 16:30 ET
|
Umoja Biopharma, Inc.
SEATTLE, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc. (Umoja), a transformative immunotherapy company creating off-the-shelf treatments that aim to extend the reach and effectiveness of...
Umoja Biopharma Announces FDA Clearance of IND Application for UB-VV111, a CD19 Directed in situ CAR T for Hematologic Malignancies
31. Juli 2024 07:00 ET
|
Umoja Biopharma, Inc.
- UB-VV111 is potentially the first in situ generated CD19 chimeric antigen receptor (CAR)-T cell therapy to be evaluated in humans in the hematology setting - - First patient expected to be dosed by...
Umoja Biopharma Announces Publication in Blood Highlighting Successful Generation of In Vivo CAR T-cells in Non-Human Primate Modeling
13. Juni 2024 08:00 ET
|
Umoja Biopharma, Inc.
Umoja Biopharma Announces Publication in Blood Highlighting Successful Generation of In Vivo CAR T-cells in Non-Human Primate Modeling
Toxicology Drug Testing Market Revenue to Cross USD 55.9 billion by 2031, Growing at a CAGR of 5.5% Says Transparency Market Research
28. August 2023 04:17 ET
|
Transparency Market Research
Wilmington, Delaware, United States, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. - The global toxicology drug testing market is projected to flourish at a CAGR of 5.5% from...
Inotiv, Inc. Announces Expansion of In Vivo Pharmacology Offering with Acquisition of Plato BioPharma, Inc.
04. Oktober 2021 16:05 ET
|
Inotiv, Inc.
WEST LAFAYETTE, Ind., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ:NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and...